Article Details

Calquence Demonstrates Sustained Survival Benefit for CLL - Pharmacy Times

Retrieved on: 2022-06-05 13:41:28

Tags for this article:

Click the tags to see associated articles and topics

Calquence Demonstrates Sustained Survival Benefit for CLL - Pharmacy Times. View article details on hiswai: https://www.pharmacytimes.com/view/calquence-demonstrates-sustained-survival-benefit-for-cll

Excerpt

Updated results from the ELEVATE-TN phase 3 trial showed AstraZeneca's Calquence (acalabrutinib) maintained a statistically significant ...

Article found on: www.pharmacytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up